

#715

# ICT01 plus Low Dose SC IL-2 Produces a Robust Anti-Tumor Immune Activation in Advanced Cancer Patients (EVICTION-2 Study)

de Bono J<sup>1</sup>, Champiat S<sup>2</sup> Danlos F-X<sup>2</sup>, Wermke M<sup>3</sup>, Kunzmann V<sup>4</sup>, De Gassart A<sup>5</sup>, Valentin E<sup>5</sup>, Iché M<sup>6</sup>, Mairesse M<sup>5</sup>, Brune P<sup>5</sup>, Lemmens K<sup>5</sup>, Olive D<sup>7</sup>, Frohna P<sup>5</sup>

1. ICR and Royal Marsden, London, UK 2. Gustave Roussy, Paris, France 3. Medical Faculty Carl Gustav Carus, Technical University, Dresden, Germany 4. University Clinic of Würzburg, Germany 5. ImCheck Therapeutics, Marseille, France 6. Ilife Consulting, Paris, France 7. CRCM, INSERM U1068, CNRS U7258, AMUIPC, Marseille, France



# 1. Background


# 2. Study Design Part 1 Dose Escalation

 $\gamma 9\delta 2$  T cell tumor infiltration is associated with a positive clinical prognosis. The anti-BTN3A mAb, ICT01, selectively activates  $\gamma$ 9 $\delta$ 2 T cells resulting in remodeling of the TME by activated  $\gamma 9\delta 2$  T, CD8 T, and NK cells (EVICTION-NCT04243499). Response to ICT01 depends on baseline  $\gamma$ 9 $\delta$ 2 T cells with many cancer patients having inadequate numbers. Eligibility criteria for the expansion cohorts in EVICTION have been instituted based on baseline  $\gamma$ 9 $\delta$ 2 T cells leading to exclusion of a significant proportion of patients.

Interleukin-2 (IL-2, Proleukin<sup>®</sup>) is an approved cancer immunotherapy shown to expand  $\gamma 9\delta 2$  T cells in humans when combined with phosphoantigen or zoledronate that decreased over multiple cycles. Combining ICT01 with IL-2 may provide a novel BTN3A-targeted approach to increase the number of circulating and tumor-resident  $\gamma$ 9 $\delta$ 2 T cells in patients resulting in a stronger anti-tumor immune response.

## ICT01 + LDSC IL-2 selectively increase circulating $\gamma$ 9 $\delta$ 2 T cells in Non-Human **Primates while blunting IL-2-mediated expansion of Tregs**

Baseline circulating  $\gamma 9\delta 2$  T cells in cancer patients are highly variable between and within indications



**Proposed MoA** l. Activation of γ982 T Cell in Periphery & Trafficking out of Circulation Phase 1/2a EVICTION-2 clinical trial: ICT01 (IV Q3W) with Proleukin® (1 or 2 MIU/m<sup>2</sup> SC Day 1-5) for the first 3 cycles, continued alone thereafter.

## Major Inclusion Criteria

### 1) ≥18 years

2) Colorectal, Ovarian, Prostate Cancer and PDAC 3) Relapsed/refractory patients who have failed at least 2 lines of systemic therapy or who failed first line therapy and are intolerant of or have a contraindication to the standard second line of therapy 4) Willingness to undergo baseline and on-study tumor biopsies 4) ECOG performance status  $\leq$  1 and life expectancy>3m 5) At least 1 measurable lesion per Response


Evaluation Criteria in Solid Tumors (RECIST)


## ICT01 IV Dose (CnD1) + Daily IL-2 SC

Cohort 1: 1mg + 1 MIU/m <sup>2</sup> (n=2)	Cohort 2: 1mg + 2 MIU/m <sup>2</sup> (n=2)
Cohort 3: $5mg + 1 MIU/m^2$ (n=5)	Cohort 4: 5mg + 1 MIU/m <sup>2</sup>
Cohort 5: 20mg + 1 MIU/m <sup>2</sup> (n=2)	Cohort 6: 20mg + 1 MIU/m <sup>2</sup>
Cohort 7: 75mg + 1 MIU/m <sup>2</sup> (n=2)	Cohort 8: 75mg + 1 MIU/m <sup>2</sup>


N = patients dosed with at least one dose of ICT01 with LDSC IL2 (09 oct 2023)

### C2D1 CnD1 C1D8\* C1D8\* C1D1 C3D1 C1D8\*





## 3. ICT01 + LDSC IL-2 has a Favorable Safety Profile



ICT1-related Adverse Events ( > 1 patient)

Total patients dosed (N) =23 (Sep 2023)

Grade 1 - Mild Grade 2 - Moderate

Grade 3 - Severe

Grade 4 - Life-Threatening/Disabling

Combination of ICT01 with LDSC-IL-2 has a good safety profile, with no dose limiting toxicities. Most frequent treatment-related adverse events are cytokine release syndrome (CRS) and infusion related reaction (IRR) that are similar to those observed with ICT01 monotherapy (EVICTION-NCT04243499), mostly Grade 1 and 2, observed also at 2<sup>nd</sup> and 3rd cycle

Cohort	Patient ID	Dx	Baseline γ9δ2 T Cells	RECIST/ iRECIST
1 1mg ICT01 1MIU/m² IL-2	01-01-201	CRC	8 111	PD W8
	01-01-203	Ovarian	192 242	SD W8/PD W16
2 1mg ICT01 2MIU/m² IL-2	01-01-204	CRC	15098	SD W8/PD W16
	01-01-206	Ovarian	6 789	PD W16
<b>3</b> 5mg ICT01 1MIU/m² IL-2	01-01-205	CRC	19 136	SD W16/iuPD W24
	04-01-202	CRC	75861	PD W8
	05-01-203	Pancreas	5 697	SD W8/PD W16
	05-01-207	Prostate	3 014	iuPD W8/PD W16
	04-01-205	Pancreas	16377	PD W8
<b>5</b> 20mg ICT01 1MIU/m² IL-2	04-01-203	CRC	18468	PD W8
	05-01-201	PDAC	0	ND
	05-01-202	Ovarian	6 512	ND
	05-01-205	Prostate	0	SD W8/PD W16
	01-01-208	CRC	6 047	PD W8



30-

20-


10-

Fold Change from baseline (D5/8/15)

Number of Patients



# 4. Effect of ICT01+LDSC IL-2 on Expansion and Activation of Circulating γ9δ2 T cells, NK, CD8 T cells and Tregs




## New dosing regimen


To further activate the expanded  $\gamma$ 9 $\delta$ 2 T cells an alternative ICT01 dosing regimen ICT01 administration was introduced. Low dose ICT01+LDSC IL2 is used to trigger  $\gamma 9\delta 2$  T cell expansion (D1).

An additional ICT01 dose is added at the peak of expansion (D8) to trigger activation and migration of a large number of  $\gamma$ 9 $\delta$ 2 T cells


ICT01 IV Dose (CnD1 and C1-3D8) + Daily IL-2 SC			
Cohort 10: 5mg/5mg + 1 MIU/m <sup>2</sup>	Cohort 11: 5mg/20mg + 2 MIU/m <sup>2</sup>		
(n=2)	(n=2)		



and increased expression of surface immune checkpoint receptors.



The expansion of  $\gamma 9\delta 2$  T cells at D8 following low dose of ICT01 on day 1 was confirmed. Adding a second dose of ICT01 at peak of expansion results is rapid migration of circulating T cells, hence confirming that these expanded cells  $\gamma 9\delta 2$  are still ICT01-responsive



CD8/Treg ratio decreases post ICT01+IL-2 reflecting superior expansion of Treg as compared to CD8 T cells in peripheral blood. High dose of ICT01 (20 or 75mg) tends to limit the decrease of CD8/Treg ratio in line with our preclinical observations in non-human primates

**5.** Conclusion

Low ICT01

High ICT01

(C1-C3)

(C5-C7)

The selective expansion of γ9δ2 T cells observed in preclinical studies has been confirmed in patients with a dvanced-stage solid tumors with a beneficial safety profile. ICT01 plus LDSC IL-2 produces a broad anti-tumor immune response that is durable across multiple treatment to prior attempts to expand y982 T cells with bisphosphonates or phosphoantigens.